PUR Biologics Begins Shipment of its Breakthrough Product PURbonedough(TM)
PURbonedough positioned to capture its share of the forecasted total spine market expected to grow from 13.3 billon in 2023 to 19 billion in 2030, a growth rate of 5.2% CAGR
PURbonedough is PURs most advanced product yet in bone regeneration, notably spinal fusion
Shipment has begun to distributors and customers with strong feedback; should be major seller in 2023
The products innovative dough-like consistency is superior in handling to currently available products
PUR Biologics, an innovative biotech company, and wholly-owned subsidiary of HippoFi, Inc. (OTC PINK: ORHB), today has unveiled its latest product, PURbonedough, to further expand its leadership into the burgeoning spine biologics market.
PURbonedough is derived from 100% donated human tissue that, through significant research and development, has been prepared to optimize the cellular conditions required for spine fusion surgeries. The product's unique composition also offers the best in market handling properties that provide confidence and assurance against graft migration.
At PUR Biologics, we are committed to developing innovative solutions that can improve patient surgical and functional outcomes, ultimately advancing patients' quality of life," said Ryan Fernan, Head of PUR Biologics.
With its extensive network of direct sales and strategic sales partners, nearing 300 sales representatives nationwide, PUR Biologics plans to launch PURbonedough and capture its share of the forecasted growth in the spine biologics market.
"We believe that PUR Biologics' continued investment in advanced biologic solutions will drive our growth and lead to long-term value creation for our shareholders." says CJ Wiggins, Founder, Executive Chairman & CEO of HippoFi.
To learn more about PURbonedough and PUR Biologics' full line of biologic products, visit www.PURbiologics.com.
----
